Controversies in osteoporosis management: Antiresorptive therapy for preventing bone loss: When to use one or two antiresorptive agents?

Research output: Contribution to journalArticle

4 Scopus citations


Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.

Original languageEnglish
Pages (from-to)749-756
Number of pages8
JournalClinical Obstetrics and Gynecology
Issue number4
StatePublished - Dec 2013


All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this